 Connection
Warren Capell to Multicenter Studies as Topic
This is a "connection" page, showing publications Warren Capell has written about Multicenter Studies as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.290 |
|
|
|
-
Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, Lipardi C, Sugarmann C, Suh E, Rao JP, Hiatt WR, Bonaca MP. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Am Heart J. 2021 05; 235:12-23.
Score: 0.147
-
Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018 05; 199:83-91.
Score: 0.120
-
Abernethy AP, Capell WH, Aziz NM, Ritchie C, Prince-Paul M, Bennett RE, Kutner JS. Ethical conduct of palliative care research: enhancing communication between investigators and institutional review boards. J Pain Symptom Manage. 2014 Dec; 48(6):1211-21.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|